Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 210
- 试验地点
- 1
- 主要终点
- Relapse
研究概览
简要总结
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is:
• Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 6 Years 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation.
排除标准
- •Patients who cannot recieve chemoterapy or allo-geneic hematopoietic stem cell transplantation.
- •Patients who cannot comply with the study.
研究组 & 干预措施
AML patients with MLL rearrangement
AML patients with MLL rearrangement who recieved chemnoptherapy or unerwent allo-SCT
干预措施: Detection of leukemia stem cell using multiparameter flow cytometry (Diagnostic Test)
结局指标
主要结局
Relapse
时间窗: Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.
Relapse was defined by the morphological evidence of disease in the peripheral blood, BM or extramedullary sites
次要结局
- leukemia-free survival(Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.)
- overall survival(Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.)
研究者
Siqi Li
Chief Technician
Peking University People's Hospital